RecruitingPhase 1NCT03911388
39
studies recruiting now
as of 7 Sept 2026
345
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
24 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingEarly phase 1NCT06959979
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
RecruitingPhase 1NCT07390539
B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1NCT07664176
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
RecruitingNCT07242963
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 39 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Medulloblastoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Medulloblastoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 17 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Carmustine (Bicnu)
Phase 2Etoposide (Etoposide)
Phase 2Cisplatin (Cisplatin)
Phase 2Pomalidomide (Imnovid)
Phase 2Carboplatin (Carboplatin)
Phase 2Vincristine
Phase 2Rivoceranib
Phase 2Vismodegib (Erivedge)
Phase 2Pacmilimab
+ 9 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).